Skip to main content


Page 4 of 12

  1. Japan is one of the Organization for Economic Co-operation and Development (OECD) countries where population aging and increasing health care expenditures (HCE) are urgent issues. Recent studies have identifie...

    Authors: Yuji Hiramatsu, Hiroo Ide, Atsuko Tsuchiya and Yuji Furui
    Citation: Health Economics Review 2022 12:6
  2. Ensuring access to health services for all is the main goal of universal health coverage (UHC) plan. Out-of-pocket (OOP) payment still remains the main source of funding for healthcare in Bangladesh. The assoc...

    Authors: Md. Mizanur Rahman, Md. Rashedul Islam, Md. Shafiur Rahman, Fahima Hossain, Ashraful Alam, Md. Obaidur Rahman, Jenny Jung and Shamima Akter
    Citation: Health Economics Review 2022 12:5
  3. Although endovascular therapy (EVT) improves clinical outcomes in patients with acute ischemic stroke, the time of EVT initiation significantly influences clinical outcomes and healthcare costs. This study eva...

    Authors: Weiyi Ni, Wolfgang G. Kunz, Mayank Goyal, Lijin Chen and Yawen Jiang
    Citation: Health Economics Review 2022 12:4
  4. Multiple Sclerosis (MS) is a chronic debilitating disease that imposes a heavy socioeconomic burden on societies. This study aimed to determine the economic burden of MS on patients using the first (CinnoVex a...

    Authors: Mehdi Rezaee, Khosro Keshavarz, Sadegh Izadi, Abdosaleh Jafari and Ramin Ravangard
    Citation: Health Economics Review 2022 12:2
  5. Tracking general trends in strategic purchasing of health financing mechanisms will highlight where country demands may exist for technical support and where progress in being made that offer opportunities for...

    Authors: Chinyere Mbachu, Chinyere Okeke, Chinonso Obayi, Agnes Gatome-Munyua, Nkechi Olalere, Ikechi Ogbonna, Benjamin Uzochukwu and Obinna Onwujekwe
    Citation: Health Economics Review 2021 11:47
  6. To estimate the out-of-pocket expenditures linked to Road Traffic Injuries in Ouagadougou, Burkina Faso, as well as the prevalence of catastrophic expenditures among those out-of-pocket payments, and to identi...

    Authors: Laurène Petitfour, Emmanuel Bonnet, Isadora Mathevet, Aude Nikiema and Valéry Ridde
    Citation: Health Economics Review 2021 11:46
  7. The aim was to determine the direct impact of the COVID-19 pandemic on Spain’s health budget.

    Authors: F. J. Carrera-Hueso, L. Álvarez-Arroyo, J. E. Poquet-Jornet, P. Vázquez-Ferreiro, R. Martínez-Gonzalbez, D. El-Qutob, M. A. Ramón-Barrios, F. Martínez-Martínez, J. L. Poveda-Andrés and C. Crespo-Palomo
    Citation: Health Economics Review 2021 11:43
  8. Vaborem is a fixed dose combination of vaborbactam and meropenem with potent activity against target Carbapenem-resistant Enterobacterales (CRE) pathogens, optimally developed for Klebsiella pneumoniae carbapenem...

    Authors: Francesco Saverio Mennini, Mario Gori, Ioanna Vlachaki, Francesca Fiorentino, Paola La Malfa, Duccio Urbinati and Massimo Andreoni
    Citation: Health Economics Review 2021 11:42
  9. High-flow nasal cannula (HFNC) oxygen is a non-invasive ventilation system that was introduced as an alternative to CPAP (continuous positive airway pressure), with a marked increase in its use in pediatric ca...

    Authors: Jefferson Antonio Buendía, Ranniery Acuña-Cordero and Carlos E. Rodriguez-Martinez
    Citation: Health Economics Review 2021 11:41
  10. During the COVID-19 pandemic, health care systems are under extreme pressure. This study analyzed health care resource use (HCRU) and costs in patients admitted to the hospital for COVID-19 and aimed to estima...

    Authors: Ergun Oksuz, Simten Malhan, Mustafa Sait Gonen, Zekayi Kutlubay, Yilmaz Keskindemirci and Fehmi Tabak
    Citation: Health Economics Review 2021 11:39
  11. Economic research on hospital palliative care faces major challenges. Observational studies using routine data encounter difficulties because treatment timing is not under investigator control and unobserved p...

    Authors: Peter May, Charles Normand, Danielle Noreika, Nevena Skoro and J. Brian Cassel
    Citation: Health Economics Review 2021 11:38
  12. Nearly 19 million people across OECD countries are living with dementia, and millions of family caregivers are affected by the disease. The costs of informal care are estimated to represent 40–75% of the total...

    Authors: Renira C. Angeles, Line I. Berge, Marie H. Gedde, Egil Kjerstad, Maarja Vislapuu, Nathalie G. Puaschitz and Bettina S. Husebo
    Citation: Health Economics Review 2021 11:37
  13. Demand-side barriers to health care are as important as supply-side factors in deterring patients from obtaining effective treatment during COVID-19. Developing countries, including Togo, have focused on reduc...

    Authors: Yaovi Tossou
    Citation: Health Economics Review 2021 11:36
  14. In the absence of electronic health records, analysis of direct healthcare costs often relies on resource utilisation data collected from patient-reported surveys. This scoping review explored the availability...

    Authors: Samira B. Jabakhanji, Jan Sorensen, Gintare Valentelyte, Lee Ann Burke, Brendan McElroy and Aileen Murphy
    Citation: Health Economics Review 2021 11:35
  15. Provision of up-to-date cost information is crucial for not only addressing knowledge gap on the cost of essential health services (EHS) but also budgeting, allocating adequate resources and improving institut...

    Authors: Diriba Feyisa, Kiddus Yitbarek and Teferi Daba
    Citation: Health Economics Review 2021 11:34
  16. Breast cancer (BC) is largely prevalent worldwide. HER2-positive BC account for roughly 20–25% of all BC cases and has an overall survival lower than other BC. Innovation on BC therapeutics is a constant, but ...

    Authors: Andreia Borges, Filipa Pereira, Patrícia Redondo, Luís Antunes, Cláudia Vieira, Pedro Antunes, Maria José Bento, Susana Sousa, José Machado Lopes, Francisco Rocha-Gonçalves, Joaquim Abreu de Sousa, Deolinda Sousa Pereira and Marina Borges
    Citation: Health Economics Review 2021 11:33
  17. Antibiotics have been overprescribed to treat infectious diseases and have generated antimicrobial resistances that reduce their effectiveness. Following the rationale behind the new paradigm of personalized m...

    Authors: F. Antoñanzas, C. A. Juárez-Castelló and R. Rodríguez-Ibeas
    Citation: Health Economics Review 2021 11:29
  18. This study evaluates the Ahead Of The Game (AOTG) mental health promotion strategy for adolescent males relative to usual practice in team based sporting club community settings, allowing for joint incremental...

    Authors: Simon Eckermann, Nikki McCaffrey, Utsana Tonmukayakul, Christian Swann and Stewart Vella
    Citation: Health Economics Review 2021 11:28
  19. Cost sharing, including copayment and coinsurance, is often used to contain medical expenditure by decreasing unnecessary or excessive use of healthcare resources. Previous studies in Japan have reported the e...

    Authors: Takumi Nishi, Toshiki Maeda, Susumu Katsuki and Akira Babazono
    Citation: Health Economics Review 2021 11:24
  20. Value-based healthcare is being extensively piloted, scaled and implemented by healthcare providers and systems around the world. However, the ability of the healthcare supply chain function to strategically c...

    Authors: Benedict Stanberry, Gerhard Bothma and Katie Harrison
    Citation: Health Economics Review 2021 11:23
  21. This study was designed to estimate economic burden of lung cancer in Turkey from payer perspective based on expert panel opinion on practice patterns in clinical practice.

    Authors: Irfan Cicin, Ergun Oksuz, Nuri Karadurmus, Simten Malhan, Mahmut Gumus, Ulku Yilmaz, Levent Cansever, Halit Cinarka, Erdogan Cetinkaya, Murat Kiyik and Ahmet Ozet
    Citation: Health Economics Review 2021 11:22
  22. Medical schools with distributed or regional programs encourage people to live, work, and learn in communities that may be economically challenged. Local spending by the program, staff, teachers, and students ...

    Authors: John C. Hogenbirk, David R. Robinson and Roger P. Strasser
    Citation: Health Economics Review 2021 11:20
  23. This study reviewed the economic evidence of rapid HIV testing versus conventional HIV testing in low-prevalence high-income countries; evaluated the methodological quality of existing economic evaluations of ...

    Authors: Olanrewaju Medu, Adegboyega Lawal, Doug Coyle and Kevin Pottie
    Citation: Health Economics Review 2021 11:19
  24. Mendelian Randomization is a type of instrumental variable (IV) analysis that uses inherited genetic variants as instruments to estimate causal effects attributable to genetic factors. This study aims to estim...

    Authors: Katherine Dick, John E. Schneider, Andrew Briggs, Pascal Lecomte, Stephane A. Regnier and Michael Lean
    Citation: Health Economics Review 2021 11:16
  25. Smoking increases the risk of complications and related costs after an orthopaedic fracture. Research in other populations suggests that a one-time payment may incentivize smoking cessation. However, little is...

    Authors: Dana Alkhoury, Jared Atchison, Antonio J. Trujillo, Kimberly Oslin, Katherine P. Frey, Robert V. O’Toole, Renan C. Castillo and Nathan N. O’Hara
    Citation: Health Economics Review 2021 11:15
  26. Pulmonary rehabilitation (PR) aims to improve disease control in patients with chronic obstructive pulmonary disease (COPD) and asthma. However, the success of PR-programs depends on the patients’ participatio...

    Authors: Kathrin Damm, Heidrun Lingner, Katharina Schmidt, Ines Aumann-Suslin, Heike Buhr-Schinner, Jochen van der Meyden and Konrad Schultz
    Citation: Health Economics Review 2021 11:14
  27. Economic-evaluations using decision analytic models such as Markov-models (MM), and discrete-event-simulations (DES) are high value adds in allocating resources. The choice of modelling method is critical beca...

    Authors: Sameera Senanayake, Nicholas Graves, Helen Healy, Keshwar Baboolal, Adrian Barnett and Sanjeewa Kularatna
    Citation: Health Economics Review 2021 11:13
  28. Disease-specific registries, documenting costs and probabilities from pharmacoeconomic studies along with health state utility values from quality-of-life studies could serve as a resource to guide researchers...

    Authors: Annesha White, Meenakshi Srinivasan, La Marcus Wingate, Samuel Peasah and Marc Fleming
    Citation: Health Economics Review 2021 11:10
  29. In developed countries around the world there is a trend to enhance the public-private collaboration in healthcare. In Spain, a decentralized country with a NHS funded with taxes and universal coverage, commis...

    Authors: María Victoria Ruiz-Mallorquí, Inmaculada Aguiar-Díaz and Beatriz González- López Valcárcel
    Citation: Health Economics Review 2021 11:9
  30. Limited financial, human and material health resources coupled with increasing demand for new-born care services require efficiency in health systems to maximize the available sources for improved health outco...

    Authors: Robert Kaba Alhassan, Edward Nketiah-Amponsah, Nana A. Y. Twum-Danso, John Bawa, Williams Kwarah, Sebnem Ucer and Abdul Fatawu Ibn Abass
    Citation: Health Economics Review 2021 11:8
  31. Teleemergency doctors support ambulance cars at the emergency site by means of telemedicine. Currently, each district has its own teleemergency doctor office (decentralized solution). This paper analyses the a...

    Authors: Steffen Fleßa, Rebekka Suess, Julia Kuntosch, Markus Krohn, Bibiana Metelmann, Joachim Paul Hasebrook, Peter Brinkrolf, Klaus Hahnenkamp, Dorothea Kohnen and Camilla Metelmann
    Citation: Health Economics Review 2021 11:7
  32. Grocery food taxes represent a stable tax revenue stream for state and municipal government during times of adverse economic shocks such as that observed under the coronavirus disease 2019 (COVID-19) pandemic....

    Authors: Lingxiao Wang, Yuqing Zheng, Steven Buck, Diansheng Dong and Harry M. Kaiser
    Citation: Health Economics Review 2021 11:5
  33. The productivity of pharmaceutical research and development (R&D) investments is declining due to high failure rates in clinical research. Recently, the US Food and Drug Administration (FDA) acknowledged that ...

    Authors: Jörg Mahlich, Arne Bartol and Srirangan Dheban
    Citation: Health Economics Review 2021 11:4

Annual Journal Metrics

  • 2022 Citation Impact
    2.4 - 2-year Impact Factor
    2.8 - 5-year Impact Factor
    1.204 - SNIP (Source Normalized Impact per Paper)
    0.836 - SJR (SCImago Journal Rank)

    2023 Speed
    11 days submission to first editorial decision for all manuscripts (Median)
    220 days submission to accept (Median)

    2023 Usage 
    483 Altmetric mentions